Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain
Pilar Ciruela
, Núria Soldevila, Juan José García-Garcia, Sebastià González-Peris, Alvaro Díaz-Conradi, Alba Redin, Belén Viñado, Conchita Izquierdo, Carmen Muñoz-Almagro, Angela Domínguez, and
Barcino Working Group
Author affiliations: CIBER de Epidemiologia y Salud Pública, Madrid, Spain (P. Ciruela, N. Soldevila, J.J. García-García, C. Muñoz-Almagro, A. Dominguez); Agència de Salut Publica de Catalunya, Barcelona, Spain (P. Ciruela, C. Izquierdo); Universitat de Barcelona, Barcelona (N. Soldevila, J.J. García-García, A. Dominguez); Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain (J.J. García-García, A. Redin, C. Muñoz-Almagro); Institut de recerca Sant Joan de Déu, Esplugues de Llobregat (J.J. García-García, C. Muñoz-Almagro); Hospital Vall d’ Hebron, Barcelona (S. González-Peris, B. Viñado); Hospital HM Nens, Barcelona (A. Díaz-Conradi); Universitat Internacional de Catalunya, Sant Cugat del Vallés, Spain (C. Muñoz-Almagro)
Main Article
Figure 1
Figure 1. Invasive pneumococcal disease cases by quarter, age group, and year, Catalonia, Spain. A) Global cases; B) 13-valent pneumococcal conjugate vaccine serotypes; C) non–13-valent pneumococcal conjugate vaccine serotypes.
Main Article
Page created: September 22, 2022
Page updated: October 24, 2022
Page reviewed: October 24, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.